[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
March 2016

Preoperative Chemoradiation in an Era of Suboptimal Clinical Staging

Author Affiliations
  • 1Department of Thoracic and Cardiovascular Surgery, University of Texas, MD Anderson Cancer Center, Houston
JAMA Surg. 2016;151(3):245-246. doi:10.1001/jamasurg.2015.4047

Gabriel et al1 have concluded that there are patients who, by current treatment guidelines, would likely receive preoperative chemoradiation who may not require it. It may be appropriate to state (although this is beyond their conclusions) that the additional unnecessary therapy may be harmful, as the FFCD 9901 trial concluded.2 Studies like these that identify subgroups of patients less likely to benefit from multimodality therapy are useful in avoiding overtreatment of patients.

First Page Preview View Large
First page PDF preview
First page PDF preview
×